Compare Biogen Inc (BIIB) vs Commvault Systems Inc (CVLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Commvault Systems Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Commvault Systems Inc trades at $141.97 (market cap $5.78B). The key difference: Biogen Inc is far larger — about 5.2× Commvault Systems Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Commvault Systems Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | CVLT | |
|---|---|---|
Market Cap | $30.13B | $5.78B |
Sector | Health | Technology |
52-Week High | $216.63 | $195.41 |
52-Week Low | $132.22 | $75.18 |
Enterprise Value | $37.20B | $5.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Commvault Systems (CVLT) trades at $141.74, up 1.66% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.42 per share, beating estimates, and has a consensus analyst price target of $172.40. Revenue growth is robust, with 2026 projections at $1.2 billion, though net income margin is expected to compress. Recent news includes a shareholder investigation and positive developments in threat scan integration.
The outlook is positive given earnings beats and subscription growth, but high valuation ratios (P/E of 89.35) and margin pressure pose risks. Investor sentiment is buoyed by analyst buy ratings (54.55%), though legal scrutiny and competitive threats require monitoring for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →
